Cutting the cost of drug development?

Nature Reviews Drug Discovery

Volumn 3, Issue 4, 2004, Pages 360-364

  Rawlins, Michael D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIINFECTIVE AGENT; BETA INTERFERON; CHOLINERGIC RECEPTOR STIMULATING AGENT; DRUG; PLACEBO; SULFANILAMIDE; THALIDOMIDE;

ARTICLE; CAPITAL; CLINICAL STUDY; CONSUMER; COST CONTROL; DRUG APPROVAL; DRUG CONTROL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; TAX; TOXICITY TESTING;

EID: 4544321119     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1347     Document Type: Article

References (20)

1. Boston Consulting Group. A Revolution in R&D: How Genomics and Genetics are Transforming the Biopharmaceutical Industry. (Boston Consulting Group, Boston, Massachusetts, 2001).
2. DiMasi, J., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
3. Relman, A. S. & Angell, M. America's other drug problem. The New Republic 16, 27-41 (2002).
4. Public Citizen. America's Other Drug Problem: a Briefing Book on the Rx Drug Debate (Public Citizen, Washington DC, 2002).
5. Grabowski, H. G. & Vernon, J. M. Returns to R&D on new introductions in the 1980s. J. Health Econ. 13, 383-406 (1994).
6. Nuffield Council on Bioethics. Pharmacogenetics: Ethical Issues. (Nuffield Council on Bioethics, London, 2003).
7. Sherman, B. & Ross, R The failure of industrialised research. Acumen J. Life Sci. 1, 121-127 (2003).
8. Harris, G. Where are all the new drugs? The New York Times (5 Oct 2003).
9. Versteegh, L. R. Science and regulatory rituals associated with the drug development process. Food Drug Law J. 52, 155-161 (1997).
10. Jefferys, D. B., Leakey, D., Lewis, J. A., Payne, S. & Rawlins, M. D. New active substances authorized in the United Kingdom between 1972 and 1994. Br. J. Clin. Pharmacol. 45, 151-156 (1998).
11. Altman, D. G. & Bland, J. M. Statistical notes. Treatment allocation in controlled trials: why randomise? BMJ 318, 1209 (1999).
12. Pocock, S. J. & Elbourne, D. R. Randomized trials or observational tribulations? N. Engl. J. Med. 342, 1907-1909 (2000).
13. Niblack, J. F. Why are drug development programs growing in size and cost? A view from industry. Food Drug Law J. 52, 151-154 (1997).
14. Peck, C. C., Rubin, D. B. & Sheiner, L. B. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clin. Pharmacol. Ther. 73, 481-490 (2003).
15. Institute of Medicine. Small Clinical Trials: Issues and Challenges (Institute of Medicine, Washington DC, 2001)
16. Concato, J., Shah, N. & Horwitz, R. I. Randomised controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342, 1887-1892 (2000).
17. Barr D. P. et al. Design considerations for AIDS trials. N. Engl. J. Med. 323, 1343-1348 (1990).
18. Senn, S. Statistical Issues in Drug Development (Wiley, Chichester, 1997).
19. Lilford, R. J. & Brauanholtz, D. The statistical basis of public policy: a paradigm shift is overdue. BMJ 313, 603-607 (1996).
20. Speigelhalter, D. J., Myles, J. P., Jones, D. R. & Abrams, K. R. Bayesian methods in health technology assessment: a review. Health Technol. Assess. 4 (38), (2000).